<DOC>
	<DOCNO>NCT02838420</DOCNO>
	<brief_summary>This randomize , multicenter , Phase III , open-label study evaluate efficacy safety alectinib versus crizotinib evaluate pharmacokinetics alectinib asian participant treatment-naive ALK-positive advanced NSCLC . Participants randomize 2:1 one two treatment group receive either alectinib ( 600 milligram [ mg ] twice daily [ BID ] ) crizotinib ( 250 mg BID ) orally , respectively .</brief_summary>
	<brief_title>A Study Evaluate Compare Efficacy Safety Alectinib Versus Crizotinib Evaluate Pharmacokinetics Alectinib Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase ( ALK ) -Positive Advanced Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis advanced recurrent ( Stage IIIB amenable multimodality treatment ) metastatic ( Stage IV ) NSCLC ALKpositive assess Ventana immunohistochemistry ( IHC ) test . Sufficient tumor tissue available perform ALK IHC require . Ventana IHC test perform designated central laboratory Life expectancy least 12 week Eastern Cooperative Oncology Group Performance Status ( ECOG PS ) 02 No history receive systemic treatment advance , recurrent ( Stage IIIB amenable multimodality treatment ) metastatic ( Stage IV ) NSCLC Adequate hematologic function : Platelet count great equal ( &gt; = ) 100×10^9 per liter ( /L ) ; absolute neutrophil count ( ANC ) &gt; =1500 cell per microliter ( cells/mcL ) ; hemoglobin &gt; =9.0 gram per deciliter ( g/dL ) Adequate renal function : estimate glomerular filtration rate ( eGFR ) calculate use Modification Diet Renal Disease ( MDRD ) formula &gt; =45 milliliter per minute per 1.73 square meter Participants must recover effect major surgery significant traumatic injury least 28 day receive first dose study treatment Measurable disease ( Response Evaluation Criteria Solid Tumors version 1.1 [ RECIST v1.1 ] ) administration study treatment Previous brain leptomeningeal metastasis allow participant asymptomatic ( e.g. , diagnose incidentally study baseline ) . Asymptomatic central nervous system ( CNS ) lesion may treat discretion investigator per local clinical practice . If participant neurological symptom sign CNS metastasis , participant must complete wholebrain radiation gamma knife irradiation treatment . In case , radiation treatment must complete &gt; =14 day enrollment disease must clinically stable For female childbearing potential , negative serum pregnancy test result must obtain within 3 day prior start study treatment For woman postmenopausal ( &gt; =12 month nontherapyinduced amenorrhea ) surgically sterile ( absence ovary and/or uterus ) , agreement remain abstinent use single combine contraceptive method result failure rate &lt; 1 % per year treatment period least 3 month last dose study drug . Abstinence acceptable line prefer usual lifestyle participant . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . Examples nonhormonal contraceptive method failure rate &lt; 1 % per year include tubal ligation , male sterilization , hormonal implant , establish , proper use combine oral injected hormonal contraceptive , certain intrauterine device . Alternatively , two method ( e.g. , two barrier method condom cervical cap ) may combine achieve failure rate &lt; 1 % per year . Barrier method must always supplement use spermicide For men , agreement remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 3 month last dose study drug . Abstinence acceptable line prefer usual lifestyle participant . Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception A malignancy within previous 3 year ( curatively treat basal cell carcinoma skin , early gastrointestinal ( GI ) cancer endoscopic resection , situ carcinoma cervix , cure cancer consider impact progressionfree survival ( PFS ) overall survival ( OS ) current NSCLC ) Any GI disorder may affect absorption oral medication , malabsorption syndrome status postmajor bowel resection Liver disease characterize : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great ( &gt; ) 3× upper limit normal ( ULN ; &gt; =5×ULN participant concurrent liver metastasis ) confirm two consecutive measurement ; Impaired excretory function ( e.g. , hyperbilirubinemia ) , synthetic function , condition decompensated liver disease coagulopathy , hepatic encephalopathy , hypoalbuminemia , ascites , bleed esophageal varix ; Acute viral active autoimmune , alcoholic , type hepatitis National Cancer Institute Common Terminology Criteria Adverse Events version 4.0 Grade 3 high toxicity previous therapy ( e.g. , radiotherapy ) ( exclude alopecia ) , show improvement strictly consider interfere current study medication History organ transplant Coadministration anticancer therapy administer study Baseline QTc &gt; 470 m symptomatic bradycardia Administration strong/potent cytochrome P4503A inhibitor inducer within 14 day prior receive first dose study treatment treatment alectinib crizotinib Administration agent potential QT interval prolong effect within 14 day prior receive first dose study drug treatment History hypersensitivity additives alectinib crizotinib drug formulation Pregnant lactate Known human immunodeficiency virus ( HIVpositivity acquire immunodeficiency syndrome ( AIDS ) relate illness Any clinically significant concomitant disease condition could interfere , treatment might interfere , conduct study absorption oral medication would , opinion Principal Investigator , pose unacceptable risk participant study Any psychological , familial , sociological , geographical condition potentially hamper compliance study protocol requirement followup procedure ; condition discuss participant study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>